At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 28 enrolled
Drug / intervention
Rosuvastatin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 1, Open-Label, Drug Interaction Study to Investigate the Effect of Single Dose Selpercatinib on the Pharmacokinetics of Rosuvastatin in Healthy Participants
In Brief
A Phase 1 clinical trial evaluating Rosuvastatin and Selpercatinib for Healthy. Completed, enrolled 28 participants across 1 site.
Detailed Summary
The main purpose of this study is to determine the effect of selpercatinib on the levels of rosuvastatin in the blood stream in healthy participants. This study also evaluated the safety and tolerability of rosuvastatin when administered in combination with selpercatinib in healthy participants. This study will last up to approximately 26 days excluding screening period.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
202420252026
First PostedJun 2023
Enrollment StartJul 2023
Primary CompletionOct 2023
TodayJul 2026
First PostedJun 18, 2023
Enrollment StartJul 27, 2023
Primary CompletionOct 31, 2023
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 3.0 years ago
Interventions
Rosuvastatindrug
Administered orally.
Selpercatinibdrug
Administered orally.